Biotech Values

[DewDiligence]

>> I may be naive but I trust that the one patient who did not respond to treatment in the 207 10mg will be an exception; i.e. that larger data will show much better efficacy than the 17% -15 letters reported by this one patient. <<

It’s not clear that removing the worst outcome from the 6-patient cohort would yield an impressive data set for the remaining five patients. We need to see more granularity than what was disclosed at the Rodman & Renshaw talk.